bioRxiv Science⌕ Search

bioRxiv · 10.1101/2023.01.31.526498

Characterization of the bioaccumulation and toxicity of copper pyrithione, an antifouling compound, on juveniles of rainbow trout

Abstract

Since the global ban on tributyltin in antifouling paints in 2008 by the International Maritime Organization, new products have been developed and brought to the market. Among them, copper pyrithione (CuPT) is used, but its mechanisms of toxicity remain little known. This project aimed to identify and measure the impacts of aqueous exposure to CuPT, an organic compound, and compare it to ionic Cu2+ added in the form of its inorganic salt CuSO4, in equivalent Cu2+ molar concentrations, on rainbow trout (Oncorhynchus mykiss) juveniles under controlled laboratory conditions. A 24-hour acute exposure was performed with nominal concentrations of 50 and 100 {micro}g/L Cu from either CuSO4 or CuPT (labelled CuSO4_50, CuSO4_100, CuPT_50 and CuPT_100, respectively). The CuPT_100 condition induced 85 % mortality in 15 hours and the CuPT_50 condition induced 5 % mortality in the same period. A chronic exposure was then performed with nominal concentrations of 1 and 10 {micro}g/L Cu from CuPT and 10 {micro}g/L Cu2+ from CuSO4 (labelled CuSO4_1, CuSO4_10, CuPT_1 and CuPT_10, respectively). Measured aqueous concentrations of Cu2+ were slightly higher than nominal concentrations for the lower concentrations, but lower for the CuPT_10 condition. The 8- and 16-day toxicokinetics showed a greater accumulation of copper in the gills of fish exposed to CuPT compared to fish exposed to Cu2+ from CuSO4. The CuPT_10 condition induced 35 and 38 % mortality after 8 and 16 days of exposure, while no mortality was observed in the CuSO4_10 condition. The growth of juveniles was not impacted during the 16 days of exposure for any condition. The activity of antioxidant enzymes (CAT, SOD, GPx) did not respond to exposure to either contaminant. The expression of genes involved in the antioxidant response (sod1, sod2, gpx), detoxification (cyp1a, mt1x, mt2x), Cu transport (ctr1, ctr2, slc11a2), energy metabolism (AcoAc, cox, 12S) and cell cycle regulation (bax) strongly decreased at Day 8 in the gills and at Day 16 in the liver of CuPT-exposed fish in comparison to controls at the same time point. This study clearly showed that the toxicity of Cu in the form of CuPT was much higher than that of ionic Cu from CuSO4 and provides new information on the compound that will be useful to develop regulations concerning its use and release in the aquatic environment. Credit author statementCharlotte Bourdon: Methodology, Validation, Investigation, Writing - Original Draft. Jerome Cachot: Conceptualization, Methodology, Validation, Investigation, Writing - Original Draft, Supervision. Patrice Gonzalez: Validation, Investigation, Writing - Original Draft, Supervision, Funding acquisition. Patrice Couture: Conceptualization, Methodology, Validation, Investigation, Writing - Original Draft, Supervision, Project administration, Funding acquisition.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bourdon, C., Cachot, J., Gonzalez, P., Couture, P.. 2023-01-31. Characterization of the bioaccumulation and toxicity of copper pyrithione, an antifouling compound, on juveniles of rainbow trout. https://doi.org/10.1101/2023.01.31.526498

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer's Disease

Neural stem cell (NSC) proliferation and differentiation in the mammalian brain decreases to minimal levels postnatally. Nevertheless, neurogenic niches persist in the adult cortex and hippocampus in rodents, primates and humans, with adult NSC differentiation sharing key regulatory mechanisms with development. Adult neurogenesis impairments have been linked to Alzheimers Disease (AD) pathology. Addressing these impairments is a promising new avenue for therapeutic intervention based on neurogenesis. However, this possibility has been hindered by technical difficulties of using in-vivo models to conduct screens, including working with scarce NSCs in the adult brain and differences between human and mouse models or ethical limitations. In our study, we use a combination of mouse and human stem cell models to circumvent these issues and perform comprehensive characterization of a novel neurogenic compound using in vitro screening. Our work focuses on the brain-derived neurotrophic factor (BDNF) pathway, a pivotal neurotrophin in the regulation of neuronal growth and differentiation via its receptor tyrosine receptor kinase B (TrkB). We describe the design, chemical synthesis and biological characterization of ENT-A011, a steroidal dehydroepiandrosterone (DHEA) derivative and BDNF mimetic with neuroprotective and neurogenic actions. The compound is able to increase proliferation of mouse primary adult hippocampal NSCs and embryonic cortical NSCs, in the absence of EGF/FGF, while reducing Amyloid-{beta} (A{beta}) induced cell death, acting specifically through TrkB activation. The compound is also able to increase astrocytic gene markers involved in NSC maintenance, protect hippocampal neurons from A{beta} toxicity and prevent synapse loss after A{beta} treatment. To provide a translational link to human cells, we also used neural progenitor cells (NPCs) differentiated from three human induced pluripotent stem cell lines from healthy and AD donors. Our findings suggest that ENT-A011 successfully induces proliferation and prevents cell death after A{beta} toxicity of human NPCs. Additionally, using RNAseq profiling, we demonstrate that the compound acts through a core gene network shared with BDNF. Our work characterizes a novel synthetic BDNF mimetic with potential neurogenic and neuroprotective actions in Alzheimers disease via stem cell-based screening, demonstrating the promise of stem cell systems for short-listing competitive candidates for further testing.

pharmacology and toxicology↗